The global Mucopolysaccharidosis (MPS) Treatment Market is poised for substantial growth, with market valuation expected to rise from USD 2.38 billion in 2022 to USD 3.37 billion by 2029, according to recent industry insights. This represents a robust compound annual growth rate (CAGR) of 5.9% during the forecast period, driven by the increasing prevalence of mucopolysaccharidosis worldwide.
MPS, a group of rare genetic disorders caused by the absence or malfunctioning of lysosomal enzymes, presents significant challenges in diagnosis and treatment. However, advancements in enzyme replacement therapies (ERTs), innovative drug development, and improved access to specialized care are contributing to the expansion of the treatment landscape. Rising awareness and early diagnosis are also fostering greater adoption of these therapies, driving market growth.
The increasing focus on precision medicine and targeted treatments has led to collaborations among biopharmaceutical companies to develop next-generation therapies for MPS. North America leads the market due to its strong healthcare infrastructure, high investment in rare disease research, and availability of advanced treatments. Meanwhile, markets in Europe and Asia-Pacific are witnessing notable growth, supported by rising healthcare expenditure and expanding access to novel therapeutics.
As the healthcare industry continues to prioritize treatments for rare genetic disorders, the MPS treatment market is expected to benefit from continued innovation and improved patient outcomes. These developments underscore the importance of collaborative efforts in addressing the unmet needs of MPS patients globally.
Key Takeaways:
- The MPS treatment market is expected to grow from USD 2.38 billion in 2022 to USD 3.37 billion by 2029, at a CAGR of 5.9%.
- Growth is driven by advancements in enzyme replacement therapies (ERTs) and increasing awareness about rare genetic disorders.
- North America leads the market, with Europe and Asia-Pacific emerging as key growth regions due to improved access to innovative treatments.
- The market underscores the potential of precision medicine and collaborative innovation in addressing the needs of MPS patients.
Competitive Landscape
Leading players operating in mucopolysaccharidosis treatment market are vigorously investing in research and development activities. They are adopted various organic and inorganic growth strategies such as mergers, new product launches and approvals, partnerships and acquisitions to gain a competitive edge in the market.
- In March 2021, JCR Pharmaceuticals Co., Ltd. announced that the approval of IZCARGO (pabinafusp alfa 10 mL, intravenous drip infusion) by Ministry of Health, Labour and Welfare (MHLW) for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome).
- In September 2021, Takeda collaborated with JCR Pharmaceutical to commercialize the next generation hunter syndrome therapy (JR-141) outside the USA
- In July 2020, Lysogene collaborated with the Weizmann Institute of Science with the aim of developing a novel AAV gene therapy approach for various genetic disorders.
- In September 2020, REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, expanded its RGX-121 program for the treatment of Mucopolysaccharidosis Type II.
- In November 2017, the USA Food and Drug Administration (FDA) approved Mepsevii for the treatment of Sly syndrome (MPS VII) in pediatric and adult persons.
Key Companies Profiled
BioMarin; Takeda Pharmaceutical Company Limited; Sanofi S.A.; Ultragenyx Pharmaceutical Inc.; Sangamo Therapeutics, Inc.; REGENXBIO Inc.; Sarepta Therapeutics; Abeona Therapeutics, Inc.
A Full Report Analysis
Mucopolysaccharidosis Treatment Market by Category
By Treatment:
- Enzyme Replacement Therapies
- Stem Cell Therapies
- Bone Marrow Transplantation
- Umbilical Cord Blood Transplantation
By Type of MPS:
- MPS I
- MPS II
- MPS IV A
- MPS VI
- MPS VII
By End User:
- Hospital
- Specialty Clinics
- Medical Research Centers
- Home-infusion
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube